Inhaled corticosteroids and pneumonia mortality in COPD patients

被引：6
作者：
Almagro, Pere [1 ]
Martinez-Camblor, Pablo [2 ]
Soriano, Joan B. [3 ,4 ]
机构：
[1] Univ Barcelona, Univ Hosp Mutua Terrassa, Internal Med Dept, Multimorbid Patients Unit, Barcelona, Spain
[2] Geisel Sch Med Dartmouth, Hanover, NH USA
[3] Univ Autonoma Madrid, Hosp Univ Princesa IISP, Madrid, Spain
[4] Inst Salud Carlos III, CIBERES, Madrid, Spain
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷 / 03期
关键词：
OBSTRUCTIVE PULMONARY-DISEASE; DOUBLE-BLIND; FLUTICASONE FUROATE; SALMETEROL-FLUTICASONE; PARALLEL-GROUP; EXACERBATIONS; RISK; COMBINATION; VILANTEROL; QVA149;
D O I：
10.1183/13993003.01035-2019
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 22 条
[21]   Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD [J].
Wedzicha, Jadwiga A. ;
Banerji, Donald ;
Chapman, Kenneth R. ;
Vestbo, Jorgen ;
Roche, Nicolas ;
Ayers, Timothy ;
Thach, Chau ;
Fogel, Robert ;
Patalano, Francesco ;
Vogelmeier, Claus F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (23) :2222-2234
[22]   LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD [J].
Zhong, Nanshan ;
Wang, Changzheng ;
Zhou, Xiangdong ;
Zhang, Nuofu ;
Humphries, Michael ;
Wang, Linda ;
Thach, Chau ;
Patalano, Francesco ;
Banerji, Donald .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 :1015-1026
123